Netarsudil Ophthalmic Solution 0.02%: First Global Approval
- 726 Downloads
Netarsudil ophthalmic solution 0.02% (hereafter referred to as netarsudil 0.02%) [Rhopressa®] is a Rho-associated protein kinase inhibitor that is thought to lower intraocular pressure (IOP) by increasing aqueous humour outflow through the trabecular meshwork. It has been developed by Aerie Pharmaceuticals and was recently approved in the USA for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. The recommended dosage is one drop in the affected eye(s) once daily in the evening. Phase III development in the EU and phase II development in Japan are underway for this indication. This article summarizes the milestones in the development of netarsudil 0.02% leading to this first approval for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Sheridan Hoy is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/61B99D70462C07ED.
- 1.Abu-Hassan DW, Acott TS, Kelley MJ. The trabecular meshwork: a basic review of form and function. J Ocul Biol. 2014;2(1).Google Scholar
- 4.Lin CW, Sherman B, Moore LA, et al. Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma. J Ocul Pharmacol Ther. 2017:1–12.Google Scholar
- 5.Aerie Pharmaceuticals Inc. RHOPRESSA® (netarsudil ophthalmic solution) 0.02%, for topical ophthalmic use: US prescribing information. 2017. https://www.fda.gov/. Accessed 16 Jan 2018.
- 6.Aerie Pharmaceuticals Inc. Aerie Pharmaceuticals announces U.S. FDA approval of Rhopressa® (netarsudil ophthalmic solution) 0.02% for the lowering of elevated IOP in patients with open-angle glaucoma or ocular hypertension. 2017. http://aeriepharma.com/. Accessed 16 Jan 2018.
- 7.Aerie Pharmaceuticals Inc. Aerie Pharmaceuticals reports positive Rocket 4 six-month topline safety and efficacy results for RhopressaTM (netarsudil ophthalmic solution) 0.02%. 2017. http://aeriepharma.com/. Accessed 16 Jan 2018.
- 8.Aerie Pharmaceuticals Inc. Aerie Pharmaceuticals initiates netarsudil ophthalmic solution phase 2 clinical trial designed to meet requirements of regulatory filing in Japan. 2017. http://aeriepharma.com/. Accessed 16 Jan
- 9.Aerie Pharmaceuticals Inc. Aerie Pharmaceuticals submits New Drug Application to U.S. Food and Drug Administration for Rhopressa(TM) (netarsudil ophthalmic solution) 0.02%. 2016. http://aeriepharma.com/. Accessed 16 Jan 2018.
- 10.Aerie Pharmaceuticals Inc. Aerie Pharmaceuticals enters into collaboration agreement with DSM focused on technology to potentially deliver Aerie compounds to treat retinal diseases such as wet AMD. 2017. http://aeriepharma.com/. Accessed 8 Feb 2018.
- 11.Aerie Pharmaceuticals Inc. Aerie Pharmaceuticals announces drug delivery asset acquisition to further advance its retinal disease program. 2017. http://aeriepharma.com/. Accessed 8 Feb 2018.
- 16.Wu K, Ren R, Li G, et al. Netarsudil increases size of giant vacuoles in Schlemm’s canal of perfused human eyes [abstract]. Invest Ophthalmol Vis Sci. 2017;58(8):1074.Google Scholar
- 17.Stamer WD, Li G, Agrahari V, et al. Rapid reversal of corticosteroid-induced ocular hypertension by netarsudil [abstract]. Invest Ophthalmol Vis Sci. 2017;58(8):3404.Google Scholar
- 18.Levy B, Ramirez N, Novack GD, et al. Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers. Am J Ophthalmol. 2015;159(5):980–5.e1.Google Scholar
- 19.Sit A. Aqueous humor dynamics of netarsudil ophthalmic solution in humans [abstract no. FP-GLA-080]. In: European Society of Ophthalmology Congress (SOE). 2017.Google Scholar
- 20.Weiss M, Levy B, Kopczynski C, et al. Evaluation of AR-13324, a novel dual mechanism agent, in lowering of IOP in glaucoma and ocular hypertension. Investig Ophthalmol Vis Sci. 2013;54(15):754.Google Scholar
- 21.Peace J, Kopczynski C, Heah T. Ocular hypotensive efficacy of netarsudil ophthalmic solution 0.02% over a 24-hour period: a pilot study [abstract]. Invest Ophthalmol Vis Sci. 2017;58(8):2460.Google Scholar
- 24.Khouri AS, Heah T, Kopczynski C, et al. A double-masked, randomized, parallel study of netarsudil ophthalmic solution, 0.02% QD compared to timolol maleate ophthalmic solution, 0.5% BID in patients with elevated intraocular pressure (ROCKET-4) [abstract]. Invest Ophthalmol Vis Sci. 2017;58(8):2461.Google Scholar